Table_1_Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial.DOCX

Background: Insomnia is a common clinical manifestation in patients with depression. Insomnia is not only a depression symptom but also an independent risk factor for recurrence. Cordyceps militaris (C. militaris) is thought to have the potential to treat insomnia. This study aimed to examine the efficacy and safety of duloxetine with C. militaris in improving sleep symptoms in patients with depression.Methods: This study was a single-center, randomized, double-blind, placebo-controlled study that recruited outpatients admitted to Beijing Anding hospital from January 2018 to January 2019. Major depressive disorder (MDD) with insomnia was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and Mini-International Neuropsychiatric Interview (M.I.N.I.). Eligible subjects will be randomly assigned to two treatment groups in a 1:1 ratio, and receive treatment and follow-up of about 6 weeks of duloxetine plus Cordyceps militaris or placebo, respectively. The severity of depression and insomnia was evaluated at baseline and at 1, 2, 4, and 6 weeks using the 17-item Hamilton Depression Scale (HAMD-17) and Athens Insomnia Scale (AIS).Results: A total of 59 subjects were included in the study (31 in the placebo group and 28 in the C. militaris group). 11 (18.6%) participants withdrew during the study period, 5 (17.9%) in the C. militaris group, and 6 (19.3%) in the placebo group. Depressive and sleep symptoms in all patients reduced over time. We found that the total scores of AIS and its subscales decreased more in the placebo group compared to the C. militaris group (p 0.05) at 1, 2, 4, and 6 weeks after treatment initiation. The incidences of adverse events were not significantly different between the two groups (all p > 0.05).Conclusion:C. militaris at the current dose and duration did not improve sleep symptoms in patients with depression, but it is safe with rare side effects.</p

Additional file 1: of Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOC 116 kb

Bacitracin-Engineered BSA/ICG Nanocomplex with Enhanced Photothermal and Photodynamic Antibacterial Activity

To reduce the drug resistance of bacteria and enhance the antibacterial ability in bacterial infection therapy, we designed a new antibacterial nanoagent. In this system, a photosensitizer (indocyanine green, ICG) was loaded in bovine serum albumin (BSA) through hydrophobic-interaction-induced self-assembly to form stable BSA@ICG nanoparticles. Furthermore, a positively charged antibacterial peptide bacitracin (Bac) was physically immobilized onto the surface of BSA@ICG to generate a bacterial-targeted nanomedicine BSA@ICG@Bac through electrostatic interactions. Afterward, its photodynamic and photothermal activities were intensely evaluated. Moreover, its bactericidal efficiency was assessed viain vitro antibacterial assays and bacterial biofilm destruction tests. First, the obtained BSA@ICG@Bac showed both good singlet oxygen generation property and high photothermal conversion efficiency. In addition, it showed enhanced photodynamic and photothermal antibacterial capacities and biofilm-removing ability in vitro due to Bac modification. To sum up, our research provided an economic and less-time-consuming approach to preparing antibacterial nanomedicines with excellent antibacterial ability. Therefore, the prepared antibacterial nanomedicines have great potential to be utilized in clinical trials in the future

sj-pdf-3-tct-10.1177_15330338231212073 - Supplemental material for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

Supplemental material, sj-pdf-3-tct-10.1177_15330338231212073 for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy by Yu Xu, Yang-Mei Xie, Wen-Sha Sun, Rong Zi, Hong-Qiao Lu, Le Xiao, Kun-Mei Gong and Shi-Kui Guo in Technology in Cancer Research & Treatment</p

sj-pdf-2-tct-10.1177_15330338231212073 - Supplemental material for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

Supplemental material, sj-pdf-2-tct-10.1177_15330338231212073 for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy by Yu Xu, Yang-Mei Xie, Wen-Sha Sun, Rong Zi, Hong-Qiao Lu, Le Xiao, Kun-Mei Gong and Shi-Kui Guo in Technology in Cancer Research & Treatment</p

sj-pdf-1-tct-10.1177_15330338231212073 - Supplemental material for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

Supplemental material, sj-pdf-1-tct-10.1177_15330338231212073 for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy by Yu Xu, Yang-Mei Xie, Wen-Sha Sun, Rong Zi, Hong-Qiao Lu, Le Xiao, Kun-Mei Gong and Shi-Kui Guo in Technology in Cancer Research & Treatment</p

sj-xlsx-7-tct-10.1177_15330338231212073 - Supplemental material for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

Supplemental material, sj-xlsx-7-tct-10.1177_15330338231212073 for Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy by Yu Xu, Yang-Mei Xie, Wen-Sha Sun, Rong Zi, Hong-Qiao Lu, Le Xiao, Kun-Mei Gong and Shi-Kui Guo in Technology in Cancer Research & Treatment</p

MOESM1 of MicroRNA profiling of diabetic atherosclerosis in a rat model

Additional file 1: Table S1. qRT-PCR analysis of AG vs. NAG relative expression levels. Table S2. DE-miR expression measured by miRNA microarray and qRT-PCR. Table S3. 3349 predicted target genes of the 9 DE-miRs. Table S4. GO analysis of target genes. Table S5. Pathway analysis of target genes. Table S6. Degree of functions in miRNA-function network. Table S7. Degree of target genes in miRNA-gene network